循环肿瘤DNA检测T790M突变的EGFR突变非小细胞肺癌患者的奥希替尼获益
在48例无组织活检、对EGFR酪氨酸激酶抑制剂获得性耐药的EGFR突变晚期非小细胞肺癌患者中,用Inivata InVision(eTAm-Seq)检测血液游离肿瘤DNA的T790M状态,50%检出T790M;可评估患者中奥希替尼部分缓解率62.5%、疾病稳定率37.5%,中位随访8个月时中位无进展生存期未达到。
要点
- ctDNA T790M检出率为50%,可替代肿瘤组织作为T790M的替代标志物。
- 可评估患者中奥希替尼部分缓解率62.5%、疾病稳定率37.5%,均为确认的缓解。
- 中位随访8个月,中位无进展生存期未达到(95% CI:4-NA),6个月和12个月无进展生存率分别为66.7%和52%。
核心结论
- 循环肿瘤DNA液体活检可作为肿瘤组织中T790M的替代标志物。
研究设计与样本
- 研究于2015年4月至2016年4月纳入48例对EGFR酪氨酸激酶抑制剂获得性耐药、无组织活检的EGFR突变晚期非小细胞肺癌患者,采用Inivata InVision(eTAm-Seq)检测ctDNA T790M突变状态。
- 进展期T790M阳性非小细胞肺癌患者接受奥希替尼80 mg每日一次治疗。
- 研究目的是评估奥希替尼的缓解率(RECIST 1.1)、无进展生存期及ctDNA中T790M阳性百分比。
主要发现
- ctDNA T790M突变在50%的非小细胞肺癌患者中检出。
- 可评估患者中奥希替尼部分缓解率为62.5%,疾病稳定率为37.5%。
- 全部缓解均为确认的缓解。
- 中位随访8个月后,按RECIST标准的中位无进展生存期未达到(95% CI:4-NA),6个月和12个月无进展生存率分别为66.7%和52%。
临床怎么用
- 作者结论认为,液体活检的ctDNA可作为肿瘤组织中T790M的替代标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients. MATERIAL AND METHODS: ctDNA T790M mutational status was assessed by Inivata InVision™ (eTAm-Seq™) assay in 48 EGFR-mutant advanced NSCLC patients with acquired resistance to EGFR TKIs without a tissue biopsy between April 2015 and April 2016. Progressing T790M-positive NSCLC patients received osimertinib (80 mg daily). The objectives were to assess the response rate to osimertinib according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, the progression-free survival (PFS) on osimertinib, and the percentage of T790M positive in ctDNA. RESULTS: The ctDNA T790M mutation was detected in 50% of NSCLC patients. Among assessable patients, osimertinib gave a partial response rate of 62.5% and a stable disease rate of 37.5%. All responses were confirmed responses. After median follow up of 8 months, median PFS by RECIST criteria was not achieved (95% CI: 4-NA), with 6- and 12-months PFS of 66.7% and 52%, respectively. CONCLUSION(S): ctDNA from liquid biopsy can be used as a surrogate marker for T790M in tumour tissue.
引用
- Remon J, Caramella C, Jovelet C, et al. Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol. 2017. PMID: 28104619. doi:10.1093/annonc/mdx017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。